Results 191 to 200 of about 87,734 (258)

Bioeconomy, sustainability, and digital technologies in Haematococcus lacustris biomass and astaxanthin production: advances and outlook

open access: yesBiofuels, Bioproducts and Biorefining, EarlyView.
Abstract Astaxanthin is a carotenoid with strong antioxidant properties, used in research on cancer treatment, ocular injuries, and neurological disorders. When produced by the microalgae Haematococcus lacustris, its antioxidant potential is even higher than that of the synthetic molecule, making it particularly attractive for pharmaceutical and ...
Renata Kühl Rocha   +5 more
wiley   +1 more source

Valorization of bark extracts from Cerrado and Amazon species: phenolic characterization, antioxidant capacity, and photoprotective potential for circular bioeconomy applications

open access: yesBiofuels, Bioproducts and Biorefining, EarlyView.
Abstract Tree bark remains an underexploited source of high‐value‐added phenolic compounds with potential circular bioeconomy applications. This work characterized bark extracts from two species of distinct Brazilian biomes, Stryphnodendron adstringens (Cerrado) and Myrcia eximia (Amazon), obtained with three solvents (ethanol, methanol and acetone ...
Mário Sérgio Lorenço   +7 more
wiley   +1 more source

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun   +4 more
wiley   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher   +7 more
wiley   +1 more source

Topographically Resolved Macular Pigment Optical Density Is Associated with Disease Progression in Macular Telangiectasia Type 2. [PDF]

open access: yesOphthalmol Sci
Raming K   +6 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy